《人类免疫缺陷病毒感染/艾滋病合并结核分枝杆菌感染诊治专家共识》解读

doi:10.16150/j.1671-2870.2022.04.003

摘要/Abstract

中图分类号:

R512.91
R52

沈银忠. 《人类免疫缺陷病毒感染/艾滋病合并结核分枝杆菌感染诊治专家共识》解读[J]. 诊断学理论与实践, 2022, 21(04): 431-436.

参考文献 25

[1]	中华医学会感染病学分会艾滋病学组, 中华医学会热带病与寄生虫学分会艾滋病学组. HIV合并结核分枝杆菌感染诊治专家共识[J]. 中华临床感染病杂志, 2017, 10(2):81-90.
	AIDS Group, Infectious Diseases Branch, Chinese Medical Association; AIDS Group, Tropical Diseases and Parasitics Branch, Chinese Medical Association. Expert consensus on diagnosis and treatment of HIV infection combined with Mycobacterium tuberculosis infection[J]. Chin J Clin Infect Dis, 2017, 10(2):81-90.
[2]	中国性病艾滋病防治协会HIV合并结核病专业委员会. 人类免疫缺陷病毒感染/艾滋病合并结核分枝杆菌感染诊治专家共识[J]. 中华传染病杂志, 2022, 40(1):6-19.
	HIV Tuberculosis Committee of China Association for STD and AIDS Prevention and Control. Expert consensus on diagnosis and treatment of Mycobacterium tuberculosis infection in patients with human immunodeficiency virus infection/acquired immunodeficiency syndrome[J]. Chin J Infect Dis, 2022, 40(1):6-19.
[3]	中国性病艾滋病防治协会HIV合并结核病专业委员会. 人类免疫缺陷病毒感染/艾滋病合并结核分枝杆菌感染诊治专家共识[J]. 新发传染病电子杂志, 2022, 7(1):73-87.
	HIV Tuberculosis Committee of China Association for STD and AIDS Prevention and Control. Expert consensus on diagnosis and treatment of Mycobacterium tuberculosis infection in patients with human immunodeficiency virus infection/acquired immunodeficiency syndrome[J]. Electron J Emerg Infect Dis, 2022, 7(1):73-87.
[4]	World Health Organization. HIV/AIDS[EB/OL]. 2021-11-30[2022-03-20]. https://www.who.int/news-room/fact-sheets/detail/hiv-aids.
[5]	World Health Organization. Global tuberculosis report 2021[M/OL]. Geneva: World Health Organization. 2021-10-14[2022-03-20]. https://www.who.int/publications/i/item/9789240037021.
[6]	Bell LCK, Noursadeghi M. Pathogenesis of HIV-1 and Mycobacterium tuberculosis co-infection[J]. Nat Rev Microbiol, 2018, 16(2):80-90. doi: 10.1038/nrmicro.2017.128 URL
[7]	吴雪韵, 沈银忠. 人类免疫缺陷病毒与结核分枝杆菌合并感染发病机制的研究进展[J]. 内科理论与实践, 2019, 14(4):253-258.
	Wu XY, Shen YZ. The pathogenesis of human immunodeficiency virus and Mycobacterium tuberculosis co-infection: research progress and literature review[J]. J Intern Med Concepts & Pract, 2019, 14(4):253-258.
[8]	郭静, 沈银忠. HIV感染/AIDS合并结核病的临床及免疫学特点研究进展[J]. 诊断学理论与实践, 2021, 20(4):401-406.
	Guo J, Shen YZ. Progress in study on clinical and immunological features of HIV/AIDS complicated with tuberculosis[J]. J Diagn Concepts & Pract, 2021, 20(4):401-406.
[9]	WHO operational handbook on tuberculosis (Module 1: prevention): tuberculosis preventive treatment[M/OL]. Geneva, World Health Organization. 2020[2021-03-20]. https://apps.who.int/iris/bitstream/handle/10665/331525/9789240002906-eng.pdf.
[10]	Luo B, Sun J, Cai R, et al. Spectrum of opportunistic infections and risk factors for in-hospital mortality of admitted AIDS patients in Shanghai[J]. Medicine (Baltimore), 2016, 95(21):e3802. doi: 10.1097/MD.0000000000003802 URL
[11]	Qi T, Zhang R, Shen Y, et al. Etiology and clinical features of 229 cases of bloodstream infection among Chinese HIV/AIDS patients: a retrospective cross-sectional study[J]. Eur J Clin Microbiol Infect Dis, 2016, 35(11):1767-1770. doi: 10.1007/s10096-016-2724-7 URL
[12]	Qi TK, Chen J, Zhang RF, et al. A retrospective cohort study of early mortality among patients with HIV/TB co-infection in Shanghai municipality[J]. HIV Med, 2020, 21(11):739-746. doi: 10.1111/hiv.13025 pmid: 33369033
[13]	Swindells S, Ramchandani R, Gupta A, et al. One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis[J]. N Engl J Med, 2019, 380(11):1001-1011. doi: 10.1056/NEJMoa1806808 URL
[14]	Agizew T, Basotli J, Alexander H, et al. Higher-than-expected prevalence of non-tuberculous mycobacteria in HIV setting in Botswana: Implications for diagnostic algorithms using Xpert MTB/RIF assay[J]. PLoS One, 2017, 12(12):e0189981.
[15]	Dorman SE, Nahid P, Kurbatova EV, et al. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis[J]. N Engl J Med, 2021, 384(18):1705-1718. doi: 10.1056/NEJMoa2033400 URL
[16]	World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach[M/OL]. Geneva: World Health Organization. 2021-07-16 [2022-03-21]. https://www.who.int/publications/i/item/9789240031593.
[17]	WHO operational handbook on tuberculosis. Module 4: treatment-drug-resistant tuberculosis treatment[M/OL]. Geneva: World Health Organization, 2020[2022-03-21]. https://www.who.int/publications-detail-redirect/9789240006997.
[18]	中华医学会结核病学分会. 中国耐多药和利福平耐药结核病治疗专家共识(2019年版)[J]. 中华结核和呼吸杂志, 2019, 42(10):733-749.
	Chinese Society of Tuberculosis of Chinese Medical Association. Chinese expert consensus on multidrug-resistant tuberculosis and Rifampicin-resistant tuberculosis treatment[J]. Chin J Tuberc & Respir Dis, 2019, 42(10):733-749.
[19]	中华医学会感染病学分会艾滋病丙型肝炎学组, 中国疾病预防控制中心. 中国艾滋病诊疗指南(2021年版)[J]. 中华内科杂志, 2021, 60(12):1106-1128.
	AIDS Hepatitis C Group, Infectious Diseases Branch, Chinese Medical Association, China Center for Disease Control and Prevention. Chinese guidelines for diagnosis and treatment of HIV/AIDS (2021 edition)[J]. Chin J Intern Med, 2021, 60(12):1106-1128.
[20]	Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services[EB/OL]. 2022-01-20[2022-03-21]. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf.
[21]	European AIDS Clinical Society. EACS Guidelines (Version 11.0)[EB/OL]. 2021-10[2022-03-21]. https://www.eacsociety.org/media/final2021eacsguidelinesv11.0_oct2021.pdf.
[22]	Dooley KE, Kaplan R, Mwelase N, et al. Dolutegravir-based antiretroviral therapy for patients coinfected with tuberculosis and human immunodeficiency virus: a multicenter, noncomparative, open-label, randomized Trial[J]. Clin Infect Dis, 2020, 70(4):549-556. doi: 10.1093/cid/ciz256 pmid: 30918967
[23]	de Castro N, Marcy O, Chazallon C, et al. Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial[J]. Lancet Infect Dis, 2021, 21(6):813-822. doi: 10.1016/S1473-3099(20)30869-0 URL
[24]	Kendall MA, Lalloo U, Fletcher CV, et al. Safety and Pharmacokinetics of double-dose lopinavir/ritonavir + rifampin versus lopinavir/ritonavir + daily rifabutin for treatment of human immunodeficiency virus-tuberculosis coinfection[J]. Clin Infect Dis, 2021, 73(4):706-715. doi: 10.1093/cid/ciab097 URL
[25]	Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America[EB/OL]. 2022-02-17[2022-03-21]. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf.

《人类免疫缺陷病毒感染/艾滋病合并结核分枝杆菌感染诊治专家共识》解读

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 25

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈志敏, 何浩岚. 艾滋病合并马尔尼菲篮状菌病的诊治现状[J]. 诊断学理论与实践, 2022, 21(04): 425-430.
[2]	陈志敏, 刘波, 何浩岚, 何耀祖, 冯理智, 刘新华, 张坚生, 蔡卫平, 李凌华. 133例艾滋病合并马尔尼菲篮状菌病死亡病例分析[J]. 诊断学理论与实践, 2022, 21(04): 444-449.
[3]	胡静静, 吕海伟, 荀静娜, 沈银忠, 刘莉, 卢洪洲. 2012年至2021年上海市艾滋病合并分枝杆菌感染患者的菌种分布特征[J]. 诊断学理论与实践, 2022, 21(04): 450-455.
[4]	陈宏, 沈银忠. 人类免疫缺陷病毒感染/艾滋病合并结核病的诊治进展[J]. 诊断学理论与实践, 2022, 21(04): 530-534.
[5]	程齐俭, 陈聆, 杜威, 柳亚慧, 杨华, 肖和平, 时国朝. 首次复治肺结核病结核分枝杆菌对利福平耐药性与rpoB基因RRDR突变的研究[J]. 诊断学理论与实践, 2018, 17(06): 635-639.
[6]	何梅芳, 刘健红, 陈春华, 申红玉. 全血γ-干扰素释放试验与ELISA检测结核分枝杆菌抗体在痰菌阴性肺结核辅助诊断中的比较应用[J]. 诊断学理论与实践, 2018, 17(05): 586-589.
[7]	张桂红, 夏前林, 单孟林, 郑江花. TSPOT.TB在HIV感染/AIDS合并分枝杆菌感染患者中的诊断价值[J]. 诊断学理论与实践, 2017, 16(04): 404-408.
[8]	孙勤, 肖和平,. 结核分枝杆菌耐药性分子检测方法的新进展[J]. 诊断学理论与实践, 2015, 14(05): 464-467.
[9]	潘卫,. 结核血清学诊断的现状与挑战[J]. 诊断学理论与实践, 2015, 14(01): 6-9.
[10]	陈军, 卢洪洲,. 结核分枝杆菌核酸检测的临床应用[J]. 诊断学理论与实践, 2015, 14(01): 10-12.
[11]	刘莉, 卢洪洲,. 非结核分枝杆菌肺病诊断及治疗进展[J]. 诊断学理论与实践, 2015, 14(01): 22-26.
[12]	施裕新, 马倩, 王国英, 宋风祥, 张志勇,. 获得性免疫缺陷综合征合并肺结核的影像学诊断[J]. 诊断学理论与实践, 2015, 14(01): 1-5.
[13]	郑叶, 童海涛, 曾东, 杨月香, 冯艳玲, 卢洪洲,. 艾滋病合并眼、胰腺和脾结核误诊为肿瘤3例临床与病理分析[J]. 诊断学理论与实践, 2014, 13(02): 187-192.
[14]	汤琰, 孙乔, 邵鹏, 王涛, 盛燕华, 李旭, 马平, 朱林英,. 浦东新区公安机关监测点人群HIV和TP的监测分析[J]. 诊断学理论与实践, 2013, 12(05): 553-555.
[15]	汤琰, 孙乔, 顾春华, 张鹏, 张枭, 宋爱红,. 哨点监测人群中人类免疫缺陷病毒、梅毒、丙肝病毒感染的检测结果分析[J]. 诊断学理论与实践, 2013, 12(03): 352-354.